Artiva CMO sells $12K in stock to cover taxes

Artiva Biotherapeutics’ chief medical officer executed an automatic sell-to-cover trade tied to RSU vesting, leaving him with a sizable remaining stake.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Medical Officer Subhashis Banerjee sold 1,100 shares of common stock on September 3, 2026 at $11.1556 per share. According to the company’s sell-to-cover policy, this automatic sale was made solely to cover tax withholding from vested restricted stock units, and Banerjee now holds 140,947 shares directly.

Insider Trade Summary

Net Seller: 1,100 shares

Net Sell 1 txn

Insider Banerjee Subhashis

Role Chief Medical Officer

Sold 1,100 shs ($12K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,100	$11.1556	$12K

Holdings After Transaction: Common Stock — 140,947 shares (Direct)

Footnotes (1)

1. F1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Key Figures

Shares sold: 1,100 shares Sale price per share: $11.1556 per share Approximate transaction value: $12,271.16 +1 more

4 metrics

Shares sold 1,100 shares Common stock sold on September 3, 2026

Sale price per share $11.1556 per share Price for the 1,100 common shares sold

Approximate transaction value $12,271.16 1,100 shares sold at $11.1556 per share

Shares held after transaction 140,947 shares Direct common stock holdings of the Chief Medical Officer after the sale

Key Terms

sell-to-cover, tax withholding obligations, restricted stock units

3 terms

sell-to-cover financial

"The Issuer has adopted a "sell-to-cover" policy to satisfy the tax"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

tax withholding obligations financial

"to satisfy the tax withholding obligations of the Reporting Person"

restricted stock units financial

"in connection with the vesting and release of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

What insider transaction did ARTV disclose for Chief Medical Officer Subhashis Banerjee?

Artiva Biotherapeutics disclosed that Chief Medical Officer Subhashis Banerjee sold 1,100 shares of common stock on September 3, 2026 at $11.1556 per share. The sale was tied to tax withholding on vested restricted stock units under a company sell-to-cover policy.

Was the ARTV insider sale by the Chief Medical Officer discretionary?

No. The filing states the sale was made under Artiva’s “sell-to-cover” policy to satisfy tax withholding obligations from RSU vesting, and that the sales were automatic and not at the discretion of Chief Medical Officer Subhashis Banerjee.

How many ARTV shares does the Chief Medical Officer hold after this transaction?

After selling 1,100 shares to cover taxes, Chief Medical Officer Subhashis Banerjee holds 140,947 shares of Artiva Biotherapeutics common stock directly, according to the Form 4.

What was the approximate value of the ARTV shares sold by the Chief Medical Officer?

The sale involved 1,100 shares at $11.1556 per share, for an approximate total value of $12,271.16, based on the figures reported in the Form 4.

Was the ARTV insider transaction made under a Rule 10b5-1 trading plan?

No Rule 10b5-1 plan is reported. Instead, the filing explains that the transaction was executed under the issuer’s sell-to-cover policy to meet tax withholding obligations on vested restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:03 PM Accepted by SEC EDGAR 09/04/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Banerjee Subhashis

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2026		S		1,100(1)	D	$11.1556	140,947	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

	/s/ Andrew Cronauer, Attorney-in-Fact	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)